Your browser doesn't support javascript.
loading
Novel immune checkpoint targets: A promising therapy for cancer treatments.
Patwekar, Mohsina; Sehar, Nouroz; Patwekar, Faheem; Medikeri, Anuradha; Ali, Shafat; Aldossri, Rana M; Rehman, Muneeb U.
Affiliation
  • Patwekar M; Luqman College of Pharmacy, Gulbarga, 585102, Karnataka, India. Electronic address: mohsina.patwekar@gmail.com.
  • Sehar N; Centre for Translational and Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard University, New Delhi, 110062, India.
  • Patwekar F; Luqman College of Pharmacy, Gulbarga, 585102, Karnataka, India.
  • Medikeri A; Luqman College of Pharmacy, Gulbarga, 585102, Karnataka, India.
  • Ali S; Cytogenetics and Molecular Biology Laboratory, Centre of Research for Development, University of Kashmir, Srinagar, 190006, Jammu and Kashmir, India. Electronic address: rahilshafat986@gmail.com.
  • Aldossri RM; Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.
  • Rehman MU; Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Int Immunopharmacol ; 126: 111186, 2024 Jan 05.
Article in En | MEDLINE | ID: mdl-37979454
The immune system frequently comprises immunological checkpoints. They serve as a barrier to keep the immune system from overreacting and damaging cells that are robust. Immune checkpoint inhibitors (ICIs) are utilized in immunotherapy to prevent the synergy of partner proteins of checkpoint proteins with auxiliary proteins. Moreover, the T cells may target malignant cells since the "off" signal cannot be conveyed. ICIs, which are mostly composed of monoclonal antibodies (mAbs) against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and anti- programmed death-1/programmed ligand 1 (anti-PD-1/PD-L1), might transform the context of cancer therapy. Further, more patients continued to exhibit adaptive resistance, even though several ICIs demonstrated convincing therapeutic benefits in selective tumor types. Immune checkpoint therapy's overall effectiveness is still lacking at this time. A popular area of study involves investigating additional immune checkpoint molecules. Recent research has found a number of fresh immune checkpoint targets, including NKG2A ligands, TIGIT, B7-H6 ligands, Galectin 3, TIM3, and so on. These targets have been focus of the study, and recent investigational approaches have shown encouraging outcomes. In this review article, we covered the development and present level understanding of these recently identified immune checkpoint molecules, its effectiveness and limitations.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immune Checkpoint Proteins / Neoplasms Limits: Humans Language: En Journal: Int Immunopharmacol Journal subject: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immune Checkpoint Proteins / Neoplasms Limits: Humans Language: En Journal: Int Immunopharmacol Journal subject: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Year: 2024 Document type: Article Country of publication: